Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Hormone and Metabolic Research

Volumn 43, Issue 12, 2011, Pages 832-837

  Lindholm, D P ^a   Oberg, K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 68 GA DOTATOC PE; 5 MGMT; 5 PLA; 5PNMA 2; Biomarkers; H 11C 5HTP; H CTC; H GEP NETs

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; APTAMER; CHROMOGRANIN A; DOPA; EPITHELIAL CELL ADHESION MOLECULE; FLUORINE 18; GALLIUM 68; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PENTETREOTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE; TUMOR MARKER;

ANTIBODY PRODUCTION; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER GROWTH; CIRCULATING TUMOR CELL; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM TUMOR; DISEASE CLASSIFICATION; DISEASE MARKER; ENZYME ACTIVITY; IMMUNOCHEMISTRY; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROXIMITY LIGATION ASSAY; REVIEW;

GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 82155166331     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1287794     Document Type: Review

References (49)

1. Klppel G, Couvelard A, Perren A, Komminoth P, McNicol A M, Nilsson O, Scarpa A, Scoazec J Y, Wiedenmann B, Papotti M, Rindi G, Plckinger U. Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology: 2009; 90 162 166
2. Sawyers C L. The cancer biomarker problem. Nature: 2008; 452 7187 548 552 (Pubitemid 351483368)
3. OConnor D T. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept: 1983; 6 263 280
4. OConnor D T, Deftos L J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med: 1986; 314 1145 1151 (Pubitemid 16138661)
5. Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C, Wilander E. Chromogranins new sensitive markers for neuroendocrine tumors. Acta Oncologica (Stockholm, Sweden): 1989; 28 325 329 (Pubitemid 19166889)
6. Arnold R, Wilke A, Rinke A, Mayer C, Kann P H, Klose K J, Scherag A, Hahmann M, Mller H H, Barth P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol: 2008; 6 820 827
7. Welin S, Stridsberg M, Cunnigham J, Granberg D, Skogseid B, Oberg K, Eriksson B, Janson E T. Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors. Neuroendocrinology: 2009; 89 302 307
8. Yao J C, Phan A T, Chang D Z, Wolff R A, Hess K, Gupta S, Jacobs C, Mares J E, Landgraf A N, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol: 2008; 26 4311 4318
9. Korse C, Taal B G, de Groot C A, Bakker R H, Bonfrer JM G. Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An Excellent Pair of Biomarkers for Diagnostics in Patients With Neuroendocrine Tumor. J Clin Oncol: 2009; 27 4293 4299
10. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrgger R W. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther: 1999; 13 145 153 (Pubitemid 29090008)
11. Sidhu R, McAlindon M E, Leeds J S, Skilling J, Sanders D S. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis: 2009; 18 23 26
12. Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, Peracchi M, Bardella M T, Piodi L. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis: 2009; 15 867 871
13. Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Cands B, Leon A, Poyatos R M, Gelabert M. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol: 2011; 32 13 22
14. Oberg K, Stridsberg M. Neuroendocrine Tumors in Tumor Markers. In Diamandis E P, Fritsche H A, Lilja H, Chan D W, Schwartz M K. (eds.): 2002; AACC Press Washington 339 349
15. Plckinger U, Rindi G, Arnold R, Eriksson B, Krenning E P, de Herder W W, Goede A, Caplin M, Oberg K, Reubi J C, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B. European Neuroendocrine Tumour Society Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology: 2004; 80 394 424 (Pubitemid 40874886)
16. Boudreaux J P, Klimstra D S, Hassan M M, Woltering E A, Jensen R T, Goldsmith S J, Nutting C, Bushnell D L, Caplin M E, Yao J C. North American Neuroendocrine Tumor Society (NANETS) The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas: 2010; 39 753 766
17. Hoege C, Pfander B, Moldovan G L, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature: 2002; 419 6903 135 141 (Pubitemid 35025438)
18. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, Zamboni G. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol: 1996; 27 1124 1134 (Pubitemid 26374929)
19. Clarke M R, Baker E E, Weyant R J, Hill L, Carty S E. Proliferative Activity in Pancreatic Endocrine Tumors: Association with Function, Metastases, and Survival. Endocr Pathol: 1997; 8 181 187 (Pubitemid 127499147)
20. Gentil Perret A, Mosnier J F, Buono J P, Berthelot P, Chipponi J, Balique J G, Cuilleret J, Dechelotte P, Boucheron S. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol: 1998; 109 286 293 (Pubitemid 28110570)
21. Rigaud G, Missiaglia E, Moore P S, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G, Grigolato P, Pederzoli P, Scarpa A. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res: 2001; 61 285 292 (Pubitemid 32095729)
22. Hochwald S N, Zee S, Conlon K C, Colleoni R, Louie O, Brennan M F, Klimstra D S. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol: 2002; 20 2633 2642 (Pubitemid 34575635)
23. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res: 2008; 14 7798 7803
24. Granberg D, Wilander E, Oberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab: 2000; 85 3425 3430
25. Cunningham J L, Grimelius L, Sundin A, Agarwal S, Janson E T. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta oncologica (Stockholm, Sweden): 2007; 46 747 756 (Pubitemid 47123778)
26. Bergestuen D S, Aabakken L, Holm K, Vatn M, Thiis-Evensen E. Small intestinal neuroendocrine tumors: Prognostic factors and survival. Scand J Gastroenterol: 2009; 1 8
27. Viale G, Giobbie-Hurder A, Regan M M, Coates A S, Mastropasqua M G, DellOrto P, Maiorano E, MacGrogan G, Braye S G, Ohlschlegel C, Neven P, Orosz Z, Olszewski W P, Knox F, Thrlimann B, Price K N, Castiglione-Gertsch M, Gelber R D, Gusterson B A, Goldhirsch A. Breast International Group Trial 1-98 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol: 2008; 26 5569 5575
28. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, Mishani E J, Gross D. Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (1)(1)(1)In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol: 2011; 13 583 593
29. Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, Denecke T, Pavel M, Pascher A, Wiedenmann B, Amthauer H. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 52 697 704
30. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini I J. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med: 2007; 48 508 518 (Pubitemid 47571404)
31. Koopmans K P, Neels O C, Kema I P, Elsinga P H, Sluiter W J, Vanghillewe K, Brouwers A H, Jager P L, de Vries E G. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol: 2008; 26 1489 1495
32. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab: 2005; 90 3392 3400 (Pubitemid 41014303)
33. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F- fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res: 2010; 16 978 985
34. Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti L M, Lettieri A, Salvatore M. PET/CT in cancer research: from preclinical to clinical applications. Contrast Media Mol Imaging: 2010; 5 190 200
35. Barwick T, Bencherif B, Mountz J M, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun: 2009; 30 908 917
36. Cui T, Hurtig M, Elgue G, Li S C, Veronesi G, Essaghir A, Demoulin J B, Pelosi G, Alimohammadi M, berg K, Giandomenico V. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One: 2010; 5 e16010
37. Khan M S, Tsigani T, Rashid M, Rabouhans Js, Yu D, Luong T V, Caplin M, Meyer T. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res: 2010; 17 337 345
38. Kulke M H, Hornick J L, Frauenhoffer C, Hooshmand S, Ryan D P, Enzinger P C, Meyerhardt J A, Clark J W, Stuart K, Fuchs C S, Redston M S. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res: 2009; 15 338 345
39. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce C M, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol: 2010; 28 245 255
40. Sderberg O, Leuchowius K J, Kamali-Moghaddam M, Jarvius M, Gustafsdottir S, Schallmeiner E, Gullberg M, Jarvius J, Landegren U. Proximity ligation: a specific and versatile tool for the proteomic era. Genet Eng (NY): 2007; 28 85 93
41. Schallmeiner E, Oksanen E, Ericsson O, Spngberg L, Eriksson S, Stenman U H, Pettersson K, Landegren U. Sensitive protein detection via triple-binder proximity ligation assays. Nat Meth: 2007; 4 135 137 (Pubitemid 46454681)
42. Fredriksson S, Gullberg M, Jarvius J, Olsson C, Pietras K, Gstafsdttir S M, Ostman A, Landegren U. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol: 2002; 20 473 477 (Pubitemid 34495933)
43. Gullberg M, Gstafsdttir S M, Schallmeiner E, Jarvius J, Bjarnegrd M, Betsholtz C, Landegren U, Fredriksson S. Cytokine detection by antibody-based proximity ligation. Proc Natl Acad Sci USA: 2004; 101 8420 8424 (Pubitemid 38736590)
44. Darmanis S, Nong R Y, Hammond M, Gu J, Alderborn A, Vnelid J, Siegbahn A, Gustafsdottir S, Ericsson O, Landegren U, Kamali-Moghaddam M. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics: 2010; 9 327 335
45. Rindi G Leiter A B, Kopin A S, Bordi C, Solcia E. The normal endocrine cell odddddf the gut: changing concepts and new evidences. Ann NY Acad Sci: 2004; 1014 1 12 (Pubitemid 38594786)
46. Berezovski M V, Lechmann M, Musheev M U, Mak T W, Krylov S N. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc: 2008; 130 9137 9143 (Pubitemid 352000854)
47. Andersson T, Lundquist M, Dolphin G T, Enander K, Jonsson B H, Nilsson J W, Baltzer L. The binding of human carbonic anhydrase II by functionalized folded polypeptide receptors. Chem Biol: 2005; 12 1245 1252 (Pubitemid 41628260)
48. Pu Y, Zhu Z, Liu H, Zhang J, Liu J, Tan W. Using aptamers to visualize and capture cancer cells. Anal Bioanal Chem 397 3225 3233
49. Vinik A I, Silva M P, Woltering E A, Go V L, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas: 2009; 38 876 889